| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Latozinemab Basic information |
| Product Name: | Latozinemab | | Synonyms: | Latozinemab;Research Grade Latozinemab (DHJ44201);GSK-4527223|||AL-001;Research Grade Latozinemab;Latozinemab (anti-Sortilin) | | CAS: | 2376132-27-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Latozinemab Structure]() |
| | Latozinemab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Latozinemab Usage And Synthesis |
| Uses | Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research[1][2]. | | References | [1] Sam Jackson, et al. Six months interim analysis of the phase 2 study of AL001 in frontotemporal dementia patients carrying a granulin mutation. Alzheimer's & DementiaVolume 17: Drug Development.
[2] Robert Paul, et al. AL001 Blocks the Sortilin/PGRN Interaction and is a Potential Therapy for FTD-GRN (4422). Neurology, April 13, 2021; 96 (15 Supplement). |
| | Latozinemab Preparation Products And Raw materials |
|